

FYear 2011 Outpatients

(from April 1, 2011 to March 31, 2012)

Gross patients visited ⁿ 21667
 Patients (number of IDs) 5141
 Diabetic patients 2696

Saitama Medical Center, Saitama Medical University
 Department of Endocrinology and Diabetes

Glucose control

Dr's name	Diabetic subjects excluding gestational diabetes				patients including other than DM
	A1C(first)	n	A1C(last)	n	
ALL	7.62	2696	7.26	2695	5141
Dr.A	7.31	203	7.04	207	285
Dr.B	7.62	72	7.63	92	121
Dr.C	7.49	215	7.12	129	217
Dr.D	7.79	374	7.11	351	584
Dr.E	7.61	650	7.18	664	1083
Dr.F	7.47	608	7.15	434	688
Dr.G	6.31	21	6.20	21	155
Dr.H	6.80	1	8.33	3	5
Dr.I	7.62	259	7.50	181	240
Dr.J	8.42	110	7.54	110	241
Dr.K	8.33	35	7.45	291	409
Dr.L	7.66	47	7.52	56	76
others	8.27	74	7.66	129	1037

Outpatients Newly referred (Clinic)

	Diabetes	Endocrine	Total
April	63	43	106
May	67	59	126
June	56	63	119
July	66	61	127
August	73	52	125
September	61	37	98
October	55	49	104
November	59	46	105
December	62	45	107
January	61	46	107
February	73	48	121
March	76	43	119

cf.

Admitted patients (based on the date of discharge)
 155 (dead 2, biopsy 1)

Lipid profile (Diabetics)

(mmHg)	average	SD	n	class	%
TG	145.5	100.0	2620	<200	82%
HDL-C	51.5	14.8	2584	>=40	80%
LDL-C	106.9	29.6	2561	<120	69%

Diabetics accomplishment rate (%)


HbA1c(%)	before	after
-6.9%	31.9%	43.6%
6.9-8.4%	46.2%	41.9%
8.4%-	21.9%	14.5%

Blood pressure (Diabetic)

(mmHg)	average	SD	n	class	%
systolic	130.0	17.7	2146	<130	51%
diastolic	74.6	12.1	2146	<80	67%

Saitama Medical Center, Saitama Medical University
 Fyear 2011 (from April 1, 2011 to March 31, 2012)

	n	%
all diabetic patients	2893	100%
type 1 diabetes melitus	111	3.8%
gestational diabetes mellitus	16	0.6%
diabetics without gestational DM	2877	99.4%
OHAs	1757	60.7%
OHAs only	1400	48.4%
Insulin	1006	34.8%
insulin only	715	24.7%
combination with OHA	291	10.1%
GLP-1 analogue	145	5.0%
GLP-1 analogue only	79	2.7%
combination with OHA	66	2.3%
no medication (on diet)	342	11.8%



Oral hypoglycemic Agents	n	%
Sulfonylureas	949	54.0%
Metformin	1210	68.9%
DPP-4 inhibitor	990	56.3%
Thiazolidinedione	352	20.0%
alpha-glucosidase inhibitor	284	16.2%
Glinide	177	10.1%

Insulin	n	%
Regular or Rapid-acting	833	74.5%
Intermediate or Long-acting	796	69.5%
Mixed	198	21.6%
Vials for CSII	11	0.8%

GLP-1 agonist	n	%
Liraglutide	152	104.8%
Exenatide	43	29.7%

Lipid lowering agents	n	%
statin	1001	91.5%
fibrate	89	8.1%
EPA	63	5.8%
ezetimibe	39	3.6%
cholestyramine	32	2.9%
ペリシット	5	0.5%

Anti hypertensive drugs	n	%
ARB	929	76.8%
ACEI	135	11.2%
renin inhibitor	21	1.7%
alpha, beta blocker	212	17.5%
Ca blocker	749	62.0%
diuretics	256	21.2%
others		

combination	ID analysis		From Px data	
	n	%	initial n	last n
1	757	43.1%	771	769
2	581	33.1%	587	642
3	332	18.9%	333	366
4	84	4.8%	84	95
5	3	0.2%	3	8
Total	1757		1778	1880

combination	n	%	initial n	
			initial n	initial n
1	352	35.0%	360	383
2	653	64.9%	669	620
3	1	0.1%	1	5
Total	1006		1030	1001
combination with OHA	291		292	363

combination	n	%	initial n	
			initial n	initial n
1	138	95.2%	139	136
2	7	4.8%	7	1
Total	145		146	137
combination with OHA	66		67	101

combination	n	%	initial n	
			initial n	initial n
1	1018	93.1%	1001	1033
2	69	6.3%	62	70
3	6	0.5%	5	6
4	1	0.1%	1	1
Total	1094		1069	1110

combination	n	%	initial n	
			initial n	initial n
1	558	46.2%	588	562
2	465	38.5%	445	470
3	138	11.4%	143	139
4	47	3.9%	49	47
5	1	0.1%	2	1
Total	1209		1227	1219
combination pill	73			